Patents by Inventor Scott J. Dylla

Scott J. Dylla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of delivering DLL3 antibody drug conjugates
    Patent number: 9931421
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: April 3, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • PTK7 modulators and methods of use
    Patent number: 9914784
    Abstract: PTK7 modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyper-proliferative disorders are provided.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: March 13, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Orit Foord, Scott J. Dylla, Robert A. Stull, Alex Bankovich, Alexandra Leida Liana Lazetic, Jeffrey Bernstein
  • IDENTIFICATION AND ENRICHMENT OF CELL SUBPOPULATIONS
    Publication number: 20180067120
    Abstract: Markers useful for the identification, characterization and, optionally, the enrichment or isolation of tumorigenic cells or cell subpopulations are disclosed.
    Type: Application
    Filed: September 8, 2017
    Publication date: March 8, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: SCOTT J. DYLLA, MARIANNE SANTAGUIDA, WADE C. ANDERSON, BOB Y. LIU, SAMUEL A. WILLIAMS
  • ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
    Publication number: 20180044415
    Abstract: Provided herein are novel anti-DLL3 chimeric antigen receptors and methods of using the same to treat proliferative disorders.
    Type: Application
    Filed: February 23, 2016
    Publication date: February 15, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: PAUL ANTHONY ESCARPE, SCOTT J. DYLLA, DAVID LIU, ROBERT A. STULL
  • METHODS OF DELIVERING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20180036422
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: September 1, 2017
    Publication date: February 8, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • METHODS OF MAKING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20180036421
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: September 1, 2017
    Publication date: February 8, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • Methods of delivering DLL3 antibody drug conjugates
    Patent number: 9878053
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: January 30, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-EFNA4 antibody-drug conjugates
    Patent number: 9872922
    Abstract: The present invention provides for anti-EFNA4 antibody-drug conjugates and methods for preparing and using the same.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: January 23, 2018
    Assignees: Pfizer Inc., AbbVie Stemcentrx LLC
    Inventors: Marc Isaac Damelin, Kiran Manohar Khandke, Puja Sapra, Alexander John Bankovich, Scott J. Dylla
  • ANTI-DLL3 ANTIBODY DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20180015178
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: September 1, 2017
    Publication date: January 18, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9867887
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: January 16, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Kits containing DLL3 antibody drug conjugates
    Patent number: 9861708
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: January 9, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9855343
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: January 2, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • ANTI-DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20170368195
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: September 1, 2017
    Publication date: December 28, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • ANTI SEZ6 ANTIBODIES AND METHODS OF USE
    Publication number: 20170369571
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: June 5, 2017
    Publication date: December 28, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, ROBERT A. STULL, MICHAEL TORGOV, HUI SHAO, DAVID LIU
  • ANTI-CLDN CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
    Publication number: 20170334991
    Abstract: Provided herein are novel anti-CLDN chimeric antigen receptors and methods of using the same to treat proliferative disorders.
    Type: Application
    Filed: November 4, 2015
    Publication date: November 23, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: PAUL ANTHONY ESCARPE, SCOTT J. DYLLA, ROBERT A. STULL, DAVID LIU
  • KITS CONTAINING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20170307622
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: June 7, 2017
    Publication date: October 26, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • Anti-PTK7 antibody-drug conjugates
    Patent number: 9777070
    Abstract: The present invention provides anti-PTK7 antibody-drug conjugates and methods for preparing and using the same.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: October 3, 2017
    Assignees: PFIZER INC, ABBVIE STEMCENTRX LLC
    Inventors: Marc Isaac Damelin, Puja Sapra, Alexander John Bankovich, Scott J. Dylla
  • Anti-DLL3 antibody drug conjugates for treating cancer
    Patent number: 9775916
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: October 3, 2017
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Identification and enrichment of cell subpopulations
    Patent number: 9778264
    Abstract: Markers useful for the identification, characterization and, optionally, the enrichment or isolation of tumorigenic cells or cell subpopulations are disclosed.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: October 3, 2017
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Scott J. Dylla, Marianne Santaguida, Wade C. Anderson, Bob Y. Liu, Samuel A. Williams
  • DLL3 MODULATORS AND METHODS OF USE
    Publication number: 20170274094
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: June 7, 2017
    Publication date: September 28, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO